AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00194129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
Study NCT03140839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal Rescripting
Description: A stand-alone single session intervention for social anxiety disorder
Study NCT03140839 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginal Exposure
Description: A stand-alone single session intervention for social anxiety disorder
Study NCT03140839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Counselling
Description: Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
Study NCT03974477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SALT CONTROL H equipment to control and monitor salt during cooking process
Description: Participants will use SALT CONTROL H at home during 8 weeks to cook meals with adequate salt content.
Study NCT02960243 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Description: * DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well
Study NCT02960243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: * DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well
Study NCT03539588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: trigger point dry needling
Description: placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
Study NCT03539588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
Study NCT02241590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir + Placebo
Description: The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
Study NCT02241590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Fuzheng Huayu Tablet
Description: The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
Study NCT02844634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100mg PO daily x 12 months
Description: Immediate use of daily doxycycline (12 months duration, to start immediately)
Study NCT00194129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
Study NCT00194129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
Study NCT02844634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/emtricitabine 200/300mg PO daily
Description: Daily use of tenofovir/emtricitabine
Study NCT02844634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine 200/300mg PO daily
Description: Daily use of tenofovir/emtricitabine
Study NCT02844634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100mg PO daily x 6 months
Description: Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
Study NCT00867308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 50 mg
Study NCT00867308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg
Study NCT03337659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Integrated Care
Description: FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
Study NCT05604001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hysteroscopic ablation of submucous uterine fibroid using diode laser
Description: patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy and laser ablation of the myoma
Study NCT04604561 — intervention group
Intervention type: DEVICE
Intervention: EnVisio SmartClip
Description: The Envisio SmartClip is an FDA-cleared (approved) device for localization of in-breast lesions. While using The EnVisio™ Navigation System, the system will detect the presence of the SmartClip™ Soft Tissue Marker(s) and provide real-time three-dimensional navigation during the surgery.
Study NCT04604561 — intervention group
Intervention type: DEVICE
Intervention: EnVisio™ Navigation System
Description: The EnVisio™ Navigation System acquires and analyzes electromagnetic signatures that display the relative distance, depth, and direction from the tip of the electrosurgical tool to the implanted SmartClipTM(s) within the surgeon's field of view during the procedure.
Study NCT03831386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum-Based IPC
Description: An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via suction.
Study NCT03831386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gravity-Based IPC
Description: An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via gravity.
Study NCT00194129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
Study NCT02976311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section(C/S) via the modified Misgav-Ladach technique
Description: the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique
Study NCT02976311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section via the Pfannenstiel-Kerr technique
Description: the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
Study NCT02068638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IHE first, CONT second
Description: IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
Study NCT02068638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CONT first, IHE second
Description: CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
Study NCT02068638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GLU first, GLU-FRU second
Description: : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
Study NCT02068638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GLU-FRU first, GLU second
Description: GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
Study NCT01195779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2584786A, different formulations
Description: Intramuscular injections
Study NCT01195779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK2321138A
Description: Intramuscular injections
Study NCT01195779 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Intramuscular injections
Study NCT03850717 — intervention group
Intervention type: DEVICE
Intervention: acupuncture
Description: insert in filiform needles into skin and other soft tissue to treat the illness or disorders
Study NCT01541709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
Study NCT03328481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loss-of-resistance Quadratus lumborum block
Description: ِA blunted 22-G, 11 mm, short-bevel facet needle will be introduced in the paravertebral line at the level of L3 or L4, in 30-45 degree to the skin directing it laterally. Once the skin barrier is breached, the needle will be withdrawn back so that the tip lies just under the skin. The needle will be advanced through the posterior thoracolumbar fascia and a first fast pop sensation will be felt when the needle pierced it. With further advancement of the needle, a second deep pop will be felt after it pierces the middle thoracolumbar fascia. At this point, the needle will be in the plane of the quadratus lumborum block type II. After careful aspiration, the 30 mLs of local anaesthetic will be injected. The needle will be visualized by the ultrasound by another physician to ensure safety.
Study NCT03328481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Quadratus lumborum block
Description: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 30 ml of local anesthetic (bupivacaine 0.25 %) will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
Study NCT03328481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
Study NCT03328481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
Study NCT03980548 — intervention group
Intervention type: PROCEDURE
Intervention: CABG
Description: Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
Study NCT03215069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 mg PO daily
Study NCT03215069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo PO daily
Study NCT01401595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram oxalate
Description: The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
Study NCT02990403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT02990403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT02990403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02990403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Study NCT02990403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dydrogesterone
Study NCT02148393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrification with subsequent-cycle embryo thawing/transfer
Description: The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.
Study NCT02148393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensified luteal phase support for fresh embryo transfer
Description: A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
Study NCT02148393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnyl®
Description: 1500 IU
Study NCT02148393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utrogestan®
Description: 200 mg tid
Study NCT02148393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progynova®
Description: 2 mg bid
Study NCT02148393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoBioSystem®
Description: CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
Study NCT01507181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: single dose IV ketamine, .5mg/kg infused over 40 minutes
Study NCT01507181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: single dose IV midazolam, .45mg/kg infused over 40 minutes
Study NCT02785393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: The administration of a sugar pill
Study NCT02785393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: The administration of the Doxazosin medication
Study NCT03583957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Observational only
Description: Device is only observational and used to record EEG.
Study NCT03583957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and Behavioral interaction with a seizure forecasting mobile app
Description: Participants will be interacting with a mobile app to input perceived behavioral (e.g., number of hours slept and sleepiness) and psychological (perceived stress).
Study NCT03583957 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Seizure Alerting and Prediction System
Description: The combination of Epilog (device) and the Aura app (psychological and behavioral interaction) will be used to create a real-time seizure alerting and an hourly seizure forecasting system.
Study NCT00825123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 10 mg once
Study NCT00825123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol 50 mg once
Study NCT00825123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder
Study NCT00368108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg perampanel
Description: 2 mg perampanel
Study NCT00368108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg perampanel
Description: 4 mg perampanel
Study NCT00368108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: placebo comparator
Study NCT01926028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-3A
Description: 0.5mL injection IM
Study NCT01926028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-3
Description: 0.5mL injection IM
Study NCT01926028 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: aluminum hydroxide and buffered saline
Study NCT03477578 — intervention group
Intervention type: OTHER
Intervention: freezers
Description: neuropsychological evaluation
Study NCT03477578 — intervention group
Intervention type: OTHER
Intervention: non freezers
Description: neuropsychological evaluation
Study NCT02390154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roniciclib (BAY 1000394)
Description: Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of \[14C\] roniciclib solution
Study NCT02390154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roniciclib (BAY 1000394)
Description: 5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
Study NCT02729337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITG (In This Together)
Description: Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
Study NCT03675646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intrathecal injection of 250 mcg preservative-free morphine before surgery
Study NCT03577249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dialysis Solutions
Description: Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
Study NCT00904475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm®
Description: Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
Study NCT00904475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidoderm®
Description: Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
Study NCT04605900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthopedic Footwear
Description: The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.
Study NCT04605900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Footwear
Description: In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.
Study NCT04605900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plantar Orthoses
Description: The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.